Your browser doesn't support javascript.
loading
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Mohamed, Yehia I; Duda, Dan G; Awiwi, Muhammad O; Lee, Sunyoung S; Altameemi, Lina; Xiao, Lianchun; Morris, Jeffrey S; Wolff, Robert A; Elsayes, Khaled M; Hatia, Rikita I; Qayyum, Aliya; Chamseddine, Shadi M; Rashid, Asif; Yao, James C; Mahvash, Armeen; Hassan, Manal M; Amin, Hesham M; Kaseb, Ahmed Omar.
Affiliation
  • Mohamed YI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Duda DG; Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Awiwi MO; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Altameemi L; Hurley Medical Center, Michigan State University, East Lansing, MI 48824, USA.
  • Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Morris JS; Department of Biostatistics, Epidemiology, and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Wolff RA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Elsayes KM; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Hatia RI; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Qayyum A; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Chamseddine SM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Rashid A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Yao JC; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Mahvash A; Department of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Hassan MM; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Amin HM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Oncotarget ; 13: 1314-1321, 2022 12 06.
Article in En | MEDLINE | ID: mdl-36473155
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Clinical_trials / Prognostic_studies / Qualitative_research Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Oncotarget Year: 2022 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Clinical_trials / Prognostic_studies / Qualitative_research Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Oncotarget Year: 2022 Document type: Article Affiliation country: United States